Skip to content
Invitrocue - Transforming bioanalytics
  • Home
  • About Us
    • Meet Invitrocue
    • Our Team
    • Partners
    • Corporate Governance
    • Careers
  • Oncology
    • Onco-PDO™
    • Patient FAQ
    • Physician FAQ
  • Preclinical Services
    • Overview
    • Drug Metabolism and Pharmacokinetics
    • Toxicology and Safety Assessment
    • Hepatocytes
    • 3D Cell Culture
    • Customized Assays and Disease Modelling
    • Invivocue – Humanized Mice
  • Shareholders
    • Reports
      • Financial Reports
      • Analyst Reports
    • Announcements
    • Contact Management
  • News & Resources
    • Publications
    • Conferences & Events
    • Press Releases
    • Privacy Policy
  • Contact Us
  • English
    • English
    • Deutsch
    • Español
    • Português
    • 中文 (中国)
    • 中文 (香港)
  • Home
  • About Us
    • Meet Invitrocue
    • Our Team
    • Partners
    • Corporate Governance
    • Careers
  • Oncology
    • Onco-PDO™
    • Patient FAQ
    • Physician FAQ
  • Preclinical Services
    • Overview
    • Drug Metabolism and Pharmacokinetics
    • Toxicology and Safety Assessment
    • Hepatocytes
    • 3D Cell Culture
    • Customized Assays and Disease Modelling
    • Invivocue – Humanized Mice
  • Shareholders
    • Reports
      • Financial Reports
      • Analyst Reports
    • Announcements
    • Contact Management
  • News & Resources
    • Publications
    • Conferences & Events
    • Press Releases
    • Privacy Policy
  • Contact Us
  • English
    • English
    • Deutsch
    • Español
    • Português
    • 中文 (中国)
    • 中文 (香港)

Analyst
Reports

Investors

Financial
Reports

Analyst
Reports

Press
Releases

ASX
Announcements

Investors

Financial Reports

Analyst Reports

Announcements

Shareholders

International MOU inked between chemistry and biomedical talents from Hong Kong, Singapore and Europe for late-stage cancer research enhancement.

READ MORE >
July 27, 2022

Biotech Daily May 2019 – Dr Boreham's Crucible

READ MORE >
June 13, 2019

Gordon Capital – October 2019 Research Updates

READ MORE >
February 13, 2019

NDF Research – 2019: Another year of progress expected for Onco-PDO

READ MORE >
February 7, 2019

Wise-Owl – December 2018 Updates

READ MORE >
December 19, 2018

Gordon Capital – October 2018 Research Updates

READ MORE >
November 9, 2018

Gordon Capital – October 2018 Research Updates

READ MORE >
October 27, 2018

Wise-Owl – Initiation of Coverage

READ MORE >
August 27, 2018

Gordon Capital – June Quarter 2018 Cash Flow Report

READ MORE >
August 24, 2018

NDF Research – Initiation of Coverage

READ MORE >
April 20, 2018

GET IN TOUCH

51 Science Park Road, #01-11/13 The Aries, Singapore Science Park II Singapore 117586

GENERAL / PHARMACOLOGY ENQUIRIES:

+65 6460 0497
contact@invitrocue.com

ONCO-PDO ENQUIRIES:

+65 6819 0181
onco-pdo@invitrocue.com
SAC - SINGLAS Accredited Laboratory

SERVICES

Home
About Us
Oncology
Preclinical Services
Investors
News & Resources
Contact Us

Logo Invitrocue
Icon-twitter-x Facebook-f Linkedin-in Youtube

© Copyright 2025 Invitrocue. All rights reserved
Impressum | Privacy Policy | Cookies Policy | Cookie Settings